Interlaboratory concordance in HER-2 positive breast cancer

Autor: Jonjić, Nives, Mustać, Elvira, Tomić, Snježana, Razumović Jakić, Jasminka, Šarčević, Božena, Blažičević, Valerija, Labinac Peteh, Loredana, Švagelj, Dražen, Kopjar, Andrina, Šikić Lisica, Nataša, Vrbičić, Branka, Borić, Igor
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Zdroj: Acta clinica Croatica
Volume 54.
Issue 4.
ISSN: 1333-9451
0353-9466
Popis: Accurate assessment of HER -2 status is essential for identifying patients who will benefit from HER -2 targeted therapy. The aim of the present study was to show results on the concordance between local and central laboratory testing results in HER -2 positive breast cancer patients. In cases with discordant findings, the immunohistochemical (IHC) and/or in situ hybridization (FISH/SISH) analysis was performed in central laboratories. A total of 104 out of 143 (72.72%) breast carcinoma cases were HER -2 positive (score 3+), while nearly 14% of tumors (20/43) showed weak (score 2+) and 12% (19/143) negative IHC staining (score 0 and 1+). After repeated IHC and ISH, 88% (126/143) were classified as HER -2 positive and 12% (17/143) as HER -2 negative cases. The results obtained are in agreement with many studies that confirmed similar discordance in HER -2 testing by IHC and/or FISH between local and central laboratory. Thus, our findings as well as those from other studies support the importance of regular quality assessment of the staining procedures performed and consistency of interpretation of HER -2 test results.
Ispravna procjena HER -2 statusa je osnova za pronalaženje bolesnika kojima će koristiti HER -2 ciljana terapija. Cilj istraživanja je bio prikazati rezultate podudarnosti između testiranja HER -2 pozitivnih bolesnika oboljelih od raka dojke pri mjesnom i centralnom laboratoriju. U slučajevima nepodudarnih rezultata analize imunohistokemije (IH) i/ili in situ hibridizacije su se izvodile u centralnim laboratorijima. Ukupno 104 od 143 (72,72%) slučaja karcinoma dojke su bili HER -2 pozitivni (biljeg 3+), dok je skoro 14% tumora (20/43) prikazalo nisko (biljeg 2+) i 12% (19/143) negativno imunohistokemijsko bojenje (biljeg 0 i 1+). Nakon ponovljene analize IH i ISH 88% (126/143) se klasificiralo kao HER -2 pozitivni i 12% (17/143) kao HER -2 negativni slučajevi. Dobiveni rezultati su sukladni mnogim istraživanjima koja potvrđuju slične nepodudarnosti pri HER -2 testiranju imunohistokemijom i/ili FISH analizom između mjesnog i centralnog laboratorija. Prema tome, naši rezultati kao i rezultati drugih istraživanja podupiru značenje pravilnog procjenjivanja izvođenja protokola bojenja i dosljednosti interpretacija rezultata HER -2 testiranja.
Databáze: OpenAIRE
Externí odkaz: